AAAAAA

   
Results: 1-25 | 26-45
Results: 1-25/45
A PHASE-II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISPLATIN, EPIRUBICIN AND VP-16 FOR STAGE-III UNRESECTABLE NONSMALL CELL LUNG-CANCER
Authors: IACOBELLI S IRTELLI L SACCO R MARTINO M MASCITELLI E BASILICO L SCOGNAMIGLIO M NATOLI C FUSCO O TINARI N BELTRAMI V
Citation: S. Iacobelli et al., A PHASE-II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISPLATIN, EPIRUBICIN AND VP-16 FOR STAGE-III UNRESECTABLE NONSMALL CELL LUNG-CANCER, Anticancer research, 18(3B), 1998, pp. 2081-2084
90K (MAC-2 BP) GENE-EXPRESSION IN BREAST-CANCER AND EVIDENCE FOR THE PRODUCTION OF 90K BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS
Authors: FUSCO O QUERZOLI P NENCI I NATOLI C BRAKEBUSH C ULLRICH A IACOBELLI S
Citation: O. Fusco et al., 90K (MAC-2 BP) GENE-EXPRESSION IN BREAST-CANCER AND EVIDENCE FOR THE PRODUCTION OF 90K BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS, International journal of cancer, 79(1), 1998, pp. 23-26
DIFFERENTIAL EFFECT ON TCR-CD3 STIMULATION OF A 90-KD GLYCOPROTEIN (GP90 MAC-2BP), A MEMBER OF THE SCAVENGER RECEPTOR CYSTEINE-RICH DOMAIN PROTEIN FAMILY/
Authors: SILVESTRI B CALDERAZZO F COPPOLA V ROSATO A IACOBELLI S NATOLI C ULLRICH A SURES I AZAM M BRAKEBUSH C CHIECOBIANCHI L AMADORI A
Citation: B. Silvestri et al., DIFFERENTIAL EFFECT ON TCR-CD3 STIMULATION OF A 90-KD GLYCOPROTEIN (GP90 MAC-2BP), A MEMBER OF THE SCAVENGER RECEPTOR CYSTEINE-RICH DOMAIN PROTEIN FAMILY/, Clinical and experimental immunology, 113(3), 1998, pp. 394-400
INCREASED LEVELS OF SOLUBLE P-SELECTIN IN HYPERCHOLESTEROLEMIC PATIENTS
Authors: DAVI G ROMANO M MEZZETTI A PROCOPIO A IACOBELLI S ANTIDORMI T BUCCIARELLI T ALESSANDRINI P CUCCURULLO F BON GB
Citation: G. Davi et al., INCREASED LEVELS OF SOLUBLE P-SELECTIN IN HYPERCHOLESTEROLEMIC PATIENTS, Circulation, 97(10), 1998, pp. 953-957
90K (MAC-2 BP) PREDICTS CD4 DECLINE IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS WITH CD4 COUNTS ABOVE 200 X 10(6) CELLS L/
Authors: TINARI N NATOLI C DOSTILIO N GHINELLI F SIGHINOLFI L ORTONA L TAMBURRINI E PIAZZA M CHIRIANNI A GUERRA L DIGREGORIO P IACOBELLI S
Citation: N. Tinari et al., 90K (MAC-2 BP) PREDICTS CD4 DECLINE IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS WITH CD4 COUNTS ABOVE 200 X 10(6) CELLS L/, Archives of pathology and laboratory medicine, 122(2), 1998, pp. 178-181
PROSTATIC CARCINOSARCOMA - A CASE-REPORT
Authors: PETRONE U MARASCIA G TUCCI C PETRONE D GASPARI G ANGELUCCI D IACOBELLI S
Citation: U. Petrone et al., PROSTATIC CARCINOSARCOMA - A CASE-REPORT, Oncology Reports, 4(6), 1997, pp. 1169-1170
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED TRIAL COMPARING ONDANSETRON VERSUS ONDANSETRON PLUS DEXAMETHASONE IN THE PROPHYLAXIS OF CISPLATIN-INDUCED DELAYED EMESIS
Authors: GRIDELLI C IANNIELLO GP AMBROSINI G MUSTACCHI G PEDICINI T FARRIS A IACOBELLI S ROSSI G MORETTI G ANGELINI F DELENA M DICARLO A BONSIGNORI M SABBATINI R CATALANO G ROSSI A OLIVIERI A FINA P BIANCO AR
Citation: C. Gridelli et al., A MULTICENTER, DOUBLE-BLIND, RANDOMIZED TRIAL COMPARING ONDANSETRON VERSUS ONDANSETRON PLUS DEXAMETHASONE IN THE PROPHYLAXIS OF CISPLATIN-INDUCED DELAYED EMESIS, International journal of oncology, 10(2), 1997, pp. 395-400
CLINICAL EFFICACY AND ENDOCRINE ACTIVITY OF VOROZOLE IN POSTMENOPAUSAL BREAST-CANCER PATIENTS - RESULTS OF A MULTICENTRIC PHASE-II STUDY
Authors: BOCCARDO F AMOROSO D IACOBELLI S IRTELLI L FARRIS A MUSTACCHI G MESITI M BREMA F PACINI P CORTESI E NARDINI P GUIDA G LANGENAEKEN C
Citation: F. Boccardo et al., CLINICAL EFFICACY AND ENDOCRINE ACTIVITY OF VOROZOLE IN POSTMENOPAUSAL BREAST-CANCER PATIENTS - RESULTS OF A MULTICENTRIC PHASE-II STUDY, Annals of oncology, 8(8), 1997, pp. 745-750
LACK OF EFFECTIVENESS OF ADJUVANT ALTERNATING CHEMOTHERAPY IN NODE-POSITIVE, ESTROGEN-RECEPTOR-NEGATIVE PREMENOPAUSAL BREAST-CANCER PATIENTS - RESULTS OF A MULTICENTRIC ITALIAN STUDY
Authors: BOCCARDO F RUBAGOTTI A AMOROSO D PERROTTA A SISMONDI P FARRIS A MESITI M GALLO L PACINI P VILLA E AGOSTARA B GENTA F DESANCTIS C SCOTTO T SPADARO P BUCCARAN G CAPPELLINI M BOLOGNESI A ALDRIGHETTI D TRAINA A SCHIEPPATI G SASSI M MUSTACCHI G BENETTI GP BANDUCCI S GATTI C ROLFO F IACOBELLI S IRTELLI L
Citation: F. Boccardo et al., LACK OF EFFECTIVENESS OF ADJUVANT ALTERNATING CHEMOTHERAPY IN NODE-POSITIVE, ESTROGEN-RECEPTOR-NEGATIVE PREMENOPAUSAL BREAST-CANCER PATIENTS - RESULTS OF A MULTICENTRIC ITALIAN STUDY, Cancer investigation, 15(6), 1997, pp. 505-512
EXPRESSION OF THE 90K IMMUNOSTIMULATOR GENE IS CONTROLLED BY A PROMOTER WITH UNIQUE FEATURES
Authors: BRAKEBUSCH C JALLAL B FUSCO O IACOBELLI S ULLRICH A
Citation: C. Brakebusch et al., EXPRESSION OF THE 90K IMMUNOSTIMULATOR GENE IS CONTROLLED BY A PROMOTER WITH UNIQUE FEATURES, The Journal of biological chemistry, 272(6), 1997, pp. 3674-3682
INCREASED LEVELS OF SOLUBLE P-SELECTIN IN HYPERCHOLESTEROLEMIC PATIENTS
Authors: ROMANO M MEZZETTI A PROCOPIO A IACOBELLI S COSTANTINI F BUCCIARELLI T ALESSANDRINI P BON GB CUCCURULLO F DAVI G
Citation: M. Romano et al., INCREASED LEVELS OF SOLUBLE P-SELECTIN IN HYPERCHOLESTEROLEMIC PATIENTS, Circulation, 96(8), 1997, pp. 934-934
IDENTIFICATION OF THE TUMOR-ANTIGEN 90K DOMAINS RECOGNIZED BY MONOCLONAL-ANTIBODIES SP2 AND L3 AND PREPARATION AND CHARACTERIZATION OF NOVEL ANTI-90K MONOCLONAL-ANTIBODIES
Authors: TINARI N DEGIDIO M IACOBELLI S BOWEN M STARLING G SEACHORD C DARVEAU R ARUFFO A
Citation: N. Tinari et al., IDENTIFICATION OF THE TUMOR-ANTIGEN 90K DOMAINS RECOGNIZED BY MONOCLONAL-ANTIBODIES SP2 AND L3 AND PREPARATION AND CHARACTERIZATION OF NOVEL ANTI-90K MONOCLONAL-ANTIBODIES, Biochemical and biophysical research communications, 232(2), 1997, pp. 367-372
PROTEIN 90K STIMULATES THE IMMUNE-SYSTEM IN OVARIAN-CANCER
Authors: ZEIMET AG MARTH C FUCHS D HEROLD M WIDSCHWENDTER M DAXENBICHLER G IACOBELLI S DAPUNT O
Citation: Ag. Zeimet et al., PROTEIN 90K STIMULATES THE IMMUNE-SYSTEM IN OVARIAN-CANCER, Gynakologisch-geburtshilfliche Rundschau, 36(1), 1996, pp. 44-45
TUMOR-ASSOCIATED ANTIGEN 90K ACTIVATES MYELOMONOCYTIC CELL-LINE THP-1
Authors: ALTINDAG ZZ MARTH C WERNERFELMAYER G NATOLI C ZEIMET AG WACHTER H IACOBELLI S FUCHS D
Citation: Zz. Altindag et al., TUMOR-ASSOCIATED ANTIGEN 90K ACTIVATES MYELOMONOCYTIC CELL-LINE THP-1, Cancer letters, 107(1), 1996, pp. 143-148
VIREMIA, HCV GENOTYPE AND 90K MAC-2BP LEVELS AS PREDICTORS OF RESPONSE TO A-IFN THERAPY/
Authors: ARTINI M NATOLI C COSTANZO A GRASSADONIA A PORCARI P DEGIDIO M TINARI N BALSANO C PAROLI M IACOBELLI S LEVRERO M
Citation: M. Artini et al., VIREMIA, HCV GENOTYPE AND 90K MAC-2BP LEVELS AS PREDICTORS OF RESPONSE TO A-IFN THERAPY/, Hepatology, 24(4), 1996, pp. 143-143
A PHASE-I STUDY OF 5-DAY CONTINUOUS VENOUS INFUSION OF CARBOPLATIN ATCIRCADIAN RHYTHM-MODULATED RATE COMPARED WITH CONSTANT RATE
Authors: NATOLI C SALINI V IRTELLI L MARTINO MT GARUFI C GRASSADONIA A FIORENTINO B IACOBELLI S
Citation: C. Natoli et al., A PHASE-I STUDY OF 5-DAY CONTINUOUS VENOUS INFUSION OF CARBOPLATIN ATCIRCADIAN RHYTHM-MODULATED RATE COMPARED WITH CONSTANT RATE, Anticancer research, 16(3A), 1996, pp. 1275-1279
ELEVATED SERUM LEVELS OF 90K MAC-2 BP PREDICT UNRESPONSIVENESS TO ALPHA-INTERFERON THERAPY IN CHRONIC HCV HEPATITIS PATIENTS/
Authors: ARTINI M NATOLI C TINARI N COSTANZO A MARINELLI R BALSANO C PORCARI P ANGELUCCI D DEGIDIO M LEVRERO M IACOBELLI S
Citation: M. Artini et al., ELEVATED SERUM LEVELS OF 90K MAC-2 BP PREDICT UNRESPONSIVENESS TO ALPHA-INTERFERON THERAPY IN CHRONIC HCV HEPATITIS PATIENTS/, Journal of hepatology, 25(2), 1996, pp. 212-217
CIRCULATING IMMUNOSTIMULATORY PROTEIN 90K AND SOLUBLE INTERLEUKIN-2-RECEPTOR IN HUMAN OVARIAN-CANCER
Authors: ZEIMET AG NATOLI C HEROLD M FUCHS D WINDBICHLER G DAXENBICHLER G IACOBELLI S DAPUNT O MARTH C
Citation: Ag. Zeimet et al., CIRCULATING IMMUNOSTIMULATORY PROTEIN 90K AND SOLUBLE INTERLEUKIN-2-RECEPTOR IN HUMAN OVARIAN-CANCER, International journal of cancer, 68(1), 1996, pp. 34-38
90K (MAC-2 BP) IN HUMAN-MILK
Authors: DOSTILIO N SABATINO G NATOLI C ULLRICH A IACOBELLI S
Citation: N. Dostilio et al., 90K (MAC-2 BP) IN HUMAN-MILK, Clinical and experimental immunology, 104(3), 1996, pp. 543-546
THE IMMUNE STIMULATORY PROTEIN 90K INCREASES MAJOR HISTOCOMPATIBILITYCOMPLEX CLASS-I EXPRESSION IN A HUMAN BREAST-CANCER CELL-LINE
Authors: NATOLI C IACOBELLI S KOHN L
Citation: C. Natoli et al., THE IMMUNE STIMULATORY PROTEIN 90K INCREASES MAJOR HISTOCOMPATIBILITYCOMPLEX CLASS-I EXPRESSION IN A HUMAN BREAST-CANCER CELL-LINE, Biochemical and biophysical research communications, 225(2), 1996, pp. 617-620
THE 90K TUMOR-ASSOCIATED ANTIGEN AND CLINICAL PROGRESSION IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
Authors: IACOBELLI S ULLRICH A TINARI N ORTONA L TAMBURRINI E DEGIDIO M GHINELLI F SIGHINOLFI L PIAZZA M CHIRIANNI A GUERRA L NATOLI C
Citation: S. Iacobelli et al., THE 90K TUMOR-ASSOCIATED ANTIGEN AND CLINICAL PROGRESSION IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION, Journal of acquired immune deficiency syndromes and human retrovirology, 10(4), 1995, pp. 450-456
THE GENE (LGALS3BP) ENCODING THE SERUM-PROTEIN 90K, ASSOCIATED WITH CANCER AND INFECTION BY THE HUMAN-IMMUNODEFICIENCY-VIRUS, MAPS AT 17Q25
Authors: CALABRESE G SURES I POMPETTI F NATOLI G PALKA G IACOBELLI S
Citation: G. Calabrese et al., THE GENE (LGALS3BP) ENCODING THE SERUM-PROTEIN 90K, ASSOCIATED WITH CANCER AND INFECTION BY THE HUMAN-IMMUNODEFICIENCY-VIRUS, MAPS AT 17Q25, Cytogenetics and cell genetics, 69(3-4), 1995, pp. 223-225
A PHASE-I STUDY OF RECOMBINANT INTERFERON-ALPHA ADMINISTERED AS A 7-DAY CONTINUOUS VENOUS INFUSION AT CIRCADIAN-RHYTHM MODULATED RATE IN PATIENTS WITH CANCER
Authors: IACOBELLI S GARUFI C IRTELLI L MARTINO MT SANTOBUONO F VICARIO G TINARI N FIORENTINO B INNOCENTI P NATOLI C
Citation: S. Iacobelli et al., A PHASE-I STUDY OF RECOMBINANT INTERFERON-ALPHA ADMINISTERED AS A 7-DAY CONTINUOUS VENOUS INFUSION AT CIRCADIAN-RHYTHM MODULATED RATE IN PATIENTS WITH CANCER, American journal of clinical oncology, 18(1), 1995, pp. 27-31
HCV GENOTYPE AND SERUM 90K LEVELS - HOST AND VIRUS-RELATED FACTORS PREDICT RESPONSE TO A-IFN THERAPY
Authors: ARTINI M NATOLI C COSTANZO A TINARI N MARINELLI R ANGELUCCI D DEGIDIO M BALSANO C NATOLI G IACOBELLI S LEVRERO M
Citation: M. Artini et al., HCV GENOTYPE AND SERUM 90K LEVELS - HOST AND VIRUS-RELATED FACTORS PREDICT RESPONSE TO A-IFN THERAPY, Hepatology, 22(4), 1995, pp. 276-276
CHRONOMODULATED INFUSION OF 5-FLUOROURACIL, FOLINIC ACID AND CARBOPLATIN IN COLORECTAL-CANCER - A PILOT-STUDY
Authors: NATOLI C MARTINO MT IRTELLI L DOSTILIO N BASILICO L IACOBELLI S
Citation: C. Natoli et al., CHRONOMODULATED INFUSION OF 5-FLUOROURACIL, FOLINIC ACID AND CARBOPLATIN IN COLORECTAL-CANCER - A PILOT-STUDY, Anticancer research, 15(6B), 1995, pp. 2841-2842
Risultati: 1-25 | 26-45